Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTATATE PRRT in Pediatric NETs/Pheochromocytoma
NCT03923257Phase 2Withdrawn
- Start
- Aug 2020
- Primary completion
- Jun 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in Neuroendocrine Neoplasm (NEN), pheochromocytoma and Paraganglioma (PGL). Primary endpoints: Toxicities at 5 years and Objective Response Rate at 5 years. Planned start Aug 2020; status: withdrawn.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Neuroendocrine Neoplasm (NEN)pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT03923257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03923257.